News and Press Releases
Press releases
Theralase Demonstrates 24 Month Stability of Lead Anti-Cancer Drug
Press ReleaseToronto, Ontario – September 18, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and ...
Theralase Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug
Press ReleaseToronto, Ontario – September 12, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and t...
Theralase Anti-Cancer Drugs Effective in the Destruction of Cervical Cancer
Press ReleaseToronto, Ontario – September 5, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and th...
Theralase Increases Revenue 14% for 2Q 2017 Financial Statements
Press ReleaseToronto, Ontario – August 29, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the...
Theralase Anti-Cancer Drugs Independently Verified and Validated
Press ReleaseToronto, Ontario – August 22, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the ...
Theralase Anti-Cancer Technology Effective for the Destruction of Lung Cancer
Press ReleaseToronto, Ontario – August 8, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain an...
Theralase PDT Technology Used to Treat Fourth Patient for Bladder Cancer
Press ReleaseToronto, Ontario – August 1, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the ...
Theralase Achieves Exploratory Endpoint of Efficacy for Anti-Cancer Technology
Press ReleaseToronto, Ontario – July 25, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and...
Theralase Releases Annual and Special Meeting Videos
Press ReleaseToronto, Ontario – July 5, 2017 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain an...
Theralase Provides Clarification Regarding Certain Forward-Looking Statements
Press ReleaseToronto, Ontario – June 30, 2017 Further to its press releases dated November 1, 2016, May 1, 2017 and May 30, 2017, Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TSXV:TLT) (OTCQX: TLTFF), a leading biotech ...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
